Clinical Trials Logo
  1. Home
  2. Atypical Endometrial Hyperplasia
  3. NCT03241888

Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia

Atypical Endometrial Hyperplasia Clinical Trial

Official title:
Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia

Clinical Trial Summary

To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate or LNG-IUS alone in patients with endometrial atypical hyperplasia.

Clinical Trial Description

After diagnosed of endometrial atypical hyperplasia (EAH) by hysteroscopy, patients will be enrolled. Age, waist circumstances, blood pressure, basic history of infertility, blood pressure, serum lipid level and side effects will be collected. Blood tests, including fasting blood glucose (FBG), postprandial blood glucose (PBG), fasting insulin (FINS), SHBG, sex hormone levels, blood lipids and anti-müllerian hormone(AMH) will be performed before treatment to evacuate their metabolic conditions.

Patients are randomized to 1 of 3 treatment groups. Patients will receive MA (megestrol acetate) 160 mg by mouth daily for at least 3 months on Arm I. Patients will receive LNG-IUS insertion on Arm II and MA 160 mg plus LNG-IUS insertion on Arm III. Then an hysteroscope will be used to evaluate the endometrial condition every 3 months, and the findings will be recorded. For patients with EAH, complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypia; no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of endometrial cancer in patients. Continuous therapies will be needed in PR, NR or PD.

After completion of study treatment, 2 months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03241888
Study type Interventional
Source Fudan University
Contact
Status Completed
Phase Phase 2/Phase 3
Start date July 4, 2017
Completion date June 18, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02397083 - Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Phase 2
Recruiting NCT05647109 - Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
Completed NCT04491682 - Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia Phase 2/Phase 3
Active, not recruiting NCT00788671 - Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer Phase 2
Completed NCT04385667 - LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia Phase 2/Phase 3
Withdrawn NCT01943058 - Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer Phase 2
Withdrawn NCT04683237 - Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Completed NCT00483327 - Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate Phase 2
Recruiting NCT05316493 - Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Recruiting NCT05316935 - GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients Phase 2/Phase 3
Recruiting NCT06379113 - GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients Phase 2/Phase 3
Recruiting NCT06390904 - GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients Phase 2/Phase 3
Recruiting NCT05172999 - Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Recruiting NCT05675787 - Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia Phase 2
Active, not recruiting NCT03671811 - Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy Phase 2
Completed NCT00490087 - Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Phase 3
Terminated NCT04607252 - Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia Phase 2/Phase 3
Recruiting NCT05051722 - Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Active, not recruiting NCT00892866 - CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells N/A
Recruiting NCT03463252 - Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Phase 2/Phase 3